Back to products
Approved anticancer agents
Anticancer agents in trials
Anticancer agents in preclinical trials
Anticancer molecular libraries
Other drug agents
Bio-reagents and biochemicals
MedKoo product information:
AZD-7762 is a synthetic small molecule
inhibitor of checkpoint kinases (Chks) with potential chemosensitizing
activity. AZD7762 binds to and inhibits Chks, which may prevent cell
cycle arrest and subsequent nucleotide excision repair in DNA-damaged
tumor cells, resulting in tumor cell apoptosis. This agent may enhance
the cytotoxicity of DNA-damaging agents. Chks are protein kinases that
regulate either G1/S or G2/M transitions in the cell cycle. In the
presence of DNA damage or incomplete DNA replication, Chks become
activated and initiate cell cycle arrest to allow DNA repair or the
completion of DNA replication. Check for
active clinical trials or
closed clinical trials using this agent. (NCI
Synonym: AZD-7762; AZD 7762; AZD7762.
MedKoo Code#: 200311
Chemical Formula: C17H19FN4O2S
Exact Mass: 362.12127
Molecular Weight: 362.42
Elemental Analysis: C, 56.34; H, 5.28; F,
5.24; N, 15.46; O, 8.83; S, 8.85
Availability and price:
AZD-7762 (99%) is available in stock.
10 mg / $260.00
50 mg / $650.00
100 mg / $950.00
200 mg / $1,550.00
To inquire the quotation and lead time of custom synthesis for this agent, please send email to
firstname.lastname@example.org to describe your needs. A representative
will respond your email shortly. We offer big discount for orders of bulk quantities.
Product will be shipped with
supporting analytical data.
Information about this agent
AZD7762, a potent ATP-competitive checkpoint kinase
inhibitor in clinical trials. AZD7762 has been profiled extensively in
vitro and in vivo in combination with DNA-damaging agents and has been
shown to potentiate response in several different settings where
inhibition of checkpoint kinase results in the abrogation of DNA
damage-induced cell cycle arrest. Dose-dependent potentiation of
antitumor activity, when AZD7762 is administered in combination with
DNA-damaging agents, has been observed in multiple xenograft models with
several DNA-damaging agents, further supporting the potential of
checkpoint kinase inhibitors to enhance the efficacy of both
conventional chemotherapy and radiotherapy and increase patient response
rates in a variety of settings.
(source: Mol Cancer Ther. 2008
1: Mitchell JB, Choudhuri R, Fabre K, Sowers
AL, Citrin D, Zabludoff SD, Cook JA. In vitro and in vivo radiation
sensitization of human tumor cells by a novel checkpoint kinase
inhibitor, AZD7762. Clin Cancer Res. 2010 Apr 1;16(7):2076-84. Epub 2010
Mar 16. PubMed PMID: 20233881; PubMed Central PMCID: PMC2851146.
2: McNeely S, Conti C, Sheikh T, Patel H, Zabludoff S, Pommier Y,
Schwartz G, Tse A. Chk1 inhibition after replicative stress activates a
double strand break response mediated by ATM and DNA-dependent protein
kinase. Cell Cycle. 2010 Mar;9(5):995-1004. Epub 2010 Mar 14. PubMed
3: Goteti K, Garner CE, Utley L, Dai J, Ashwell S, Moustakas DT, Gönen
M, Schwartz GK, Kern SE, Zabludoff S, Brassil PJ. Preclinical
pharmacokinetic/pharmacodynamic models to predict synergistic effects of
co-administered anti-cancer agents. Cancer Chemother Pharmacol. 2010
Jul;66(2):245-54. Epub 2009 Oct 16. PubMed PMID: 19841922.
4: Wagner JM, Karnitz LM. Cisplatin-induced DNA damage activates
replication checkpoint signaling components that differentially affect
tumor cell survival. Mol Pharmacol. 2009 Jul;76(1):208-14. Epub 2009 Apr
29. PubMed PMID: 19403702; PubMed Central PMCID: PMC2701464.
5: Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL,
Green S, Haye HR, Horn CL, Janetka JW, Liu D, Mouchet E, Ready S,
Rosenthal JL, Queva C, Schwartz GK, Taylor KJ, Tse AN, Walker GE, White
AM. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint
abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther. 2008
Sep;7(9):2955-66. PubMed PMID: 18790776.
6: Ashwell S, Janetka JW, Zabludoff S. Keeping checkpoint kinases in
line: new selective inhibitors in clinical trials. Expert Opin Investig
Drugs. 2008 Sep;17(9):1331-40. Review. PubMed PMID: 18694366.
(Keyword; CAS#; MedKoo code#)